In addition to stimulating GLP-1 secretion in vitro and in vivo, we found that EA also greatly increased circulating PYY in mice and directly stimulated PYY release from cultured L-cells, which should be a major contributing factor for the hypophagic and anti-obesity effects of EA treatment. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.